Eric Vangrevelinghe

1.7k total citations
27 papers, 859 citations indexed

About

Eric Vangrevelinghe is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Eric Vangrevelinghe has authored 27 papers receiving a total of 859 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Organic Chemistry. Recurrent topics in Eric Vangrevelinghe's work include Cytokine Signaling Pathways and Interactions (8 papers), Computational Drug Discovery Methods (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Eric Vangrevelinghe is often cited by papers focused on Cytokine Signaling Pathways and Interactions (8 papers), Computational Drug Discovery Methods (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Eric Vangrevelinghe collaborates with scholars based in Switzerland, United States and Germany. Eric Vangrevelinghe's co-authors include Pascal Furet, Joseph Schoepfer, Robert Ernst Portmann, Doriano Fabbro, Kaspar Zimmermann, Edgar Jacoby, Gebhard Thoma, Hans‐Günter Zerwes, Gisele Tavares and Sejal Patel and has published in prestigious journals such as Blood, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Eric Vangrevelinghe

25 papers receiving 829 citations

Peers

Countries citing papers authored by Eric Vangrevelinghe

Since Specialization

Citations

This map shows the geographic impact of Eric Vangrevelinghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Vangrevelinghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Vangrevelinghe more than expected).

Fields of papers citing papers by Eric Vangrevelinghe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Vangrevelinghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Vangrevelinghe. The network helps show where Eric Vangrevelinghe may publish in the future.

Co-authorship network of co-authors of Eric Vangrevelinghe

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Vangrevelinghe. A scholar is included among the top collaborators of Eric Vangrevelinghe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Vangrevelinghe. Eric Vangrevelinghe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors 2024 ·Journal of Medicinal Chemistry ·Juraj Velcicky, Philipp Janser, Nina Gommermann, (unknown), Slavica Ilić, Eric Vangrevelinghe, Nikolaus Stiefl, Andreas Boettcher, (unknown), (unknown), Janet Dawson, Renata Murgasova, Sandrine Desrayaud, Karen Beltz, Alexandra Hinniger, Carien Dekker, Christopher J. Farady, Angela Mackay	21
2	Novel Concept for Super-Soft Topical Drugs: Deactivation by an Enzyme-Induced Switch into an Inactive Conformation 2023 ·ACS Medicinal Chemistry Letters ·Gebhard Thoma, Eric Vangrevelinghe, (unknown), Philippe Piéchon, Christian Beerli, Hans‐Günter Zerwes	0
3	Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist 2019 ·Heliyon ·(unknown), Takanori Kanazawa, Eric Vangrevelinghe, Toshiyuki Honda, Shinji Hatakeyama	5
4	Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain 2019 ·ACS Chemical Biology ·Randall McNally, Qing Li, Kunhua Li, Carien Dekker, Eric Vangrevelinghe, Matthew D. Jones, Patrick Chêne, Rainer Machauer, Thomas Radimerski, Michael J. Eck	20
5	Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model 2018 ·Journal of Medicinal Chemistry ·David A. Carcache, Anna Vulpetti, Joerg Kallen, Henri Mattes, David Orain, Rowan Stringer, Eric Vangrevelinghe, Romain M. Wolf, Klemens Kaupmann, Johannes Ottl, Janet Dawson, Nigel G. Cooke, Klemens Hoegenauer, Andreas Billich, Juergen Wagner, Christine Guntermann, Samuel Hintermann	18
6	An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome 2017 ·Frontiers in Immunology ·Heiko Sic, Matthaios Speletas, (unknown), Maximilian Seidl, Martin Beibel, Bolan Linghu, Fan Yang, (unknown), Anastasios E. Germenis, Edward J. Oakeley, Eric Vangrevelinghe, Andreas W. Sailer, Elisabetta Traggiai, Hermann Gram, Hermann Eibel	27
7	Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β 2017 ·Bioorganic & Medicinal Chemistry Letters ·Maurice J. van Eis, Jean-Pierre Evenou, W. Schüler, Gerhard Zenke, Eric Vangrevelinghe, Juergen Wagner, Peter Matt	11
8	Orally bioavailable Syk inhibitors with activity in a rat PK/PD model 2015 ·Bioorganic & Medicinal Chemistry Letters ·Gebhard Thoma, Siem J. Veenstra, (unknown), Joachim Blanz, Eric Vangrevelinghe, (unknown), Christian C. Lee, Hans‐Günter Zerwes	6
9	Discovery and Profiling of a Selective and Efficacious Syk Inhibitor 2015 ·Journal of Medicinal Chemistry ·Gebhard Thoma, Alexander B. Smith, Maurice J. van Eis, Eric Vangrevelinghe, Joachim Blanz, Reiner Aichholz, Amanda Littlewood‐Evans, Christian C. Lee, Hong Liu, Hans‐Günter Zerwes	19
10	Syk inhibitors with high potency in presence of blood 2014 ·Bioorganic & Medicinal Chemistry Letters ·Gebhard Thoma, Joachim Blanz, Peter Bühlmayer, Peter Drückes, Matthias Kittelmann, Alexander B. Smith, (unknown), Eric Vangrevelinghe, Hans‐Günter Zerwes, Jianwei Che, (unknown), Yunho Jin, Christian C. Lee, Pierre‐Yves Michellys, Tetsuo Uno, Hong Liu	17
11	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension 2014 ·Bioorganic & Medicinal Chemistry Letters ·Duncan Shaw, (unknown), Nicolas Soldermann, Elizabeth R. Sprague, W. Schüler, Eric Vangrevelinghe, Nicholas Duggan, Matthew J. Thomas, Takatoshi Kosaka, Nigel J. Waters, Maurice J. van Eis	35
12	Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs) 2014 ·Blood ·Loretta S. Li, Shuo-Chieh Wu, Nadja Kopp, Joan Montero, Jeremy Ryan, Bjoern Chapuy, (unknown), Jacob V. Layer, Oliver Weigert, Amanda L. Christie, Alexandra Christodoulou, Huiyun Liu, Akinori Yoda, Francesco Hofmann, Fabienne Baffert, Eric Vangrevelinghe, Christoph Gaul, Thomas Radimerski, Anthony Letai, David M. Weinstock	1
13	2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes 2011 ·Bioorganic & Medicinal Chemistry Letters ·Maurice J. van Eis, Jean-Pierre Evenou, Philipp Floersheim, Christoph Gaul, Sandra W. Cowan‐Jacob, Lauren G. Monovich, Gabriele Rummel, W. Schüler, Wilhelm Stark, André Strauss, (unknown), Eric Vangrevelinghe, Juergen Wagner, Nicolas Soldermann	27
14	Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition 2011 ·Blood ·Oliver Weigert, Andrew A. Lane, Liat Bird, Nadja Kopp, Angela V. Toms, Christoph Gaul, Eric Vangrevelinghe, Alain De Pover, Catherine H. Régnier, Dirk Erdmann, Francesco Hofmann, Michael J. Eck, Andrew L. Kung, Thomas Radimerski, David M. Weinstock	4
15	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Marc Gerspacher, Pascal Furet, Carole Pissot‐Soldermann, Christoph Gaul, Philipp Holzer, Eric Vangrevelinghe, Marc Lang, Dirk Erdmann, Thomas Radimerski, Catherine H. Régnier, Patrick Chêne, Alain De Pover, Francesco Hofmann, Fabienne Baffert, Thomas Buhl, Reiner Aichholz, Francesca Blasco, (unknown), Jörg Trappe, Peter Drueckes	21
16	Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Carole Pissot‐Soldermann, Marc Gerspacher, Pascal Furet, Christoph Gaul, Philipp Holzer, Clive McCarthy, Thomas Radimerski, Catherine H. Régnier, Fabienne Baffert, Peter Drueckes, Gisele Tavares, Eric Vangrevelinghe, Francesca Blasco, Giorgio Ottaviani, (unknown), (unknown), (unknown)	33
17	Computational Approaches for Fragment Optimization 2007 ·Current Computer - Aided Drug Design ·Eric Vangrevelinghe, Simon Rüdisser	9
18	New Scoring Functions for Virtual Screening from Molecular Dynamics Simulations with a Quantum-Refined Force-Field (QRFF-MD). Application to Cyclin-Dependent Kinase 2 2005 ·Journal of Chemical Information and Modeling ·(unknown), A. Curioni, Eric Vangrevelinghe, (unknown), Tiziana Mordasini, Wanda Andreoni, Pierre Acklin, Edgar Jacoby	17
19	Molecular Informatics as an Enabling in silico Technology Platform for Drug Discovery 2004 ·CHIMIA International Journal for Chemistry ·Edgar Jacoby, Ansgar Schuffenhauer, (unknown), Khalil Azzaoui, Eric Vangrevelinghe, John P. Priestle, Philippe Ferrara, Bernard Faller, Pierre Acklin	3
20	Molecular modelling of poly(methylidene malonate 2.1.2) using a continuum solvation approach 1999 ·Polymer International ·Eric Vangrevelinghe, Pascal Breton, (unknown), Luc Morin‐Allory	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact